NEURACAP
Sector OutlookPublished · 23 pages · Free to read

Biotechnology Sector Outlook — September 2026

A sector outlook on 85 biotechnology companies, showing how clinical-stage pipelines and launched biologics revenue price differently, and what buyers have paid in recent transactions. For boards and management teams benchmarking a biotech business.

For information only. Not an appraisal or a fairness opinion.

What moved since: Biotechnology M&A update, 14–28 September 2026

Key figures

Sector median multiple
4.7x
EV / Revenue, CY2027E
Premium-tier multiple
27.1x
Top 12 of 47 rated companies
Discount-tier multiple
1.8x
Bottom 11 of 47 rated companies
Largest disclosed transaction
$11.3B
argenx SE / Forte Biosciences, Inc.

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY

Biotechnology: One Label, Two Different Markets

How the sector's companies price against one another, what separates the two ends of the range, and what buyers have agreed to pay in the recorded transactions.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Biotechnology Coverage | September 2026 | Confidential | Not investment advice

1

1 / 23

Executive summary

Biotechnology trades as two markets under one sector label. Across the 47 of 85 companies with a usable forward-revenue multiple, the range runs from 27.1x at the top to 1.8x at the bottom, a gap linked more closely to pipeline stage and margin than to revenue growth. The nine recorded transactions in this report show the largest disclosed deal values going to clinical-stage targets. For any company in this sector, the peer set and the valuation argument should start with which of these two markets it belongs to.

Key findings

  • Clinical-stage pipelines and launched biologics trade on very different multiples.
  • The top of the range trades at 27.1x forward revenue; the bottom at 1.8x.
  • Faster revenue growth carries only a modest valuation premium (4.5x vs 3.9x).
  • Top disclosed deal values went to clinical-stage targets, not launched-product firms.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY

    Cover page introducing the Biotechnology sector outlook as of September 2026.

    We open with the single finding that shapes everything that follows: biotechnology prices as two different markets under one label. This deck walks through where that split shows up in the numbers, what it means for how a business should be benchmarked, and what buyers have actually paid in recent deals.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY Biotechnology: One Label, Two Different Markets How the sector's companies price against one another, what separates the two ends of the range, and what buyers have agreed to pay in the recorded transactions. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Lists the report's five sections plus the appendix.

    This report runs in five sections plus an appendix, starting with the bottom line so a reader who stops early still gets the whole story. We'll move from the market map into valuation and situations, then into the precedent transactions and what they imply for strategy. Each section builds on the last, so we recommend following the order, but nothing here requires it.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Biotechnology Does Not Trade as One Market 02 The Landscape 77 of the 85 Names Sit in One Group; The Rest Price on Marketed Revenue 03 Valuation & Situations The Range Runs from Early Pipelines at the Top to Launched Revenue at the Bottom 04 Precedent Transactions What Buyers Agreed to Pay Across Nine Recorded Transactions 05 Strategic Implications What Moves a Name up the Range from Here 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Biotechnology Trades as Two Markets: Clinical-Stage Pipelines and Launched Biologics Revenue

    States the deck's core finding that biotechnology trades as two separate markets defined by pipeline stage versus launched revenue.

    Across the 47 of 85 companies with a usable forward-revenue multiple, the middle of the range sits at 4.7x, but the top 12 trade at 27.1x and the bottom 11 at 1.8x — a spread wide enough that no single sector multiple describes this group. The split lines up with business model: 77 of the 85 names are diversified clinical-stage biotechs, priced at a 5.8x median, against 1.6x for the five biosimilars and specialty biologics names. Growth alone explains only part of the gap — the faster-growing half sits at 4.5x versus 3.9x for the slower half — so pipeline stage and margin do more of the work. So what: getting a company's peer set right starts with knowing which of these two markets it actually belongs to.

    Everything on this page

    01 · THE BOTTOM LINE Biotechnology Trades as Two Markets: Clinical-Stage Pipelines and Launched Biologics Revenue The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (47 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (47 of 85 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Two Ends of This Market Are Priced Far Apart Across the 47 names with a forward estimate, out of 85 companies screened, the middle of the range sits at 4.7x forward revenue, with the 12 names at the top at 27.1x and the 11 at the bottom at 1.8x. Forward revenue is the working lens here, with 15 of 85 names carrying a meaningful forward EBITDA. 2 The Faster Growers Carry Only a Modest Premium Splitting the 36 names with a growth estimate at 17% forward revenue growth, the 18 faster-growing names sit at 4.5x and the 18 slower-growing ones at 3.9x. That step is small against the full width of the range, so the top-line rate is associated with only part of what separates these companies. 3 Clinical-Stage Pipelines and Launched Biologics Are Underwritten on Different Terms 77 of the 85 companies are diversified clinical-stage biotechs and sit at 5.8x in the middle of that group, against 1.6x for the five biosimilars and specialty biologics names. One group is read on readouts, probability of technical and regulatory success and exclusivity runway; the other on gross-to-net, payer coverage and biosimilar entry. 4 The Top of the Recorded Deal Values Went to Clinical-Stage Targets Of the 9 transactions in this record, argenx SE completed its acquisition of Forte Biosciences, Inc. at $11.3B and AbbVie Inc. completed Apogee Therapeutics, Inc. at $10.8B. Both targets were clinical-stage, a pattern consistent with large-cap biopharma adding externally validated science ahead of exclusivity cliffs. 4.7x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 7 of 85 names are… 27.1x Premium end EV/Revenue vs 1.8x at the discount end top quartile (n=12) against bottom quartile (n=11) on EV/Revenue — the spread the report explains 51 Transactions with disclosed terms 131 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Divider introducing the market-map section covering how the 85 companies split by business segment.

    Before we get into pricing, we map where the 85 names actually sit. Most of the value — and most of the names — cluster in one segment, and that concentration sets up everything in this section.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE 77 of the 85 Names Sit in One Group; The Rest Price on Marketed Revenue Four groups, four different underwriting conversations. 02 of 06 Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Biotechnology Holds 77 of the 85 Names, and That Is Where the Value Sits

    Shows that 77 of the 85 biotechnology companies sit in one business segment, which is where most of the value concentrates.

    77 of the 85 companies in this universe are grouped in a single segment, and that's also where the group's value concentrates. The remaining names split across a handful of smaller segments, each with its own median EV / Revenue. So what: a peer group built without checking segment membership will mix two different underwriting stories.

    Everything on this page

    02 · MARKET MAP Biotechnology Holds 77 of the 85 Names, and That Is Where the Value Sits 85 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 DIVERSIFIED CLINICAL-STAGE BIOTECH 77 cos median 5.8x MRNA REGN RVMD ROIV ASND BBIO ARWR PCVX BLTE COGT TLX PTCT CELC CRSP TARS IDYA ACAD RCUS ZLAB ADMA DNLI +56 more The body of the sector: value rests on pipeline stage, data packages and the runway to the next readout. BIOSIMILARS AND SPECIALTY BIOLOGICS 5 cos median 1.6x LNTH ALVO HCM EBS EOLS Commercial-stage revenue, underwritten on payer coverage, gross-to-net and biosimilar entry rather than on pipeline value. DIVERSIFIED BIOPHARMA WITH MARKETED BIOLOGICS 2 cos median 5.5x AZN AMGN Two large marketed platforms that sit on both sides of the table — peers on the page and buyers in the record. ADJACENT: RESEARCH TOOLS AND DIAGNOSTICS 1 cos 2.2x · 1 rated OPK A boundary marker: tools and diagnostics are underwritten on visible earnings and capacity, a different frame from pipeline value.

  6. 06
    02 · LANDSCAPE

    Four Groups Under One Label, and Each Answers to a Different Set of Questions

    Breaks the market map into four segment groups, each priced and questioned differently.

    We split the approved universe into four groups, and each one answers to a different set of underwriting questions — from early-stage pipeline risk to marketed-product economics. The group medians on EV / Revenue make the differences concrete rather than descriptive. So what: the label 'biotechnology' hides real differences in what drives value group to group.

    Everything on this page

    02 · LANDSCAPE Four Groups Under One Label, and Each Answers to a Different Set of Questions Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Diversified clinical-stage biotech 77 91% 5.8x Moderna, Inc. (MRNA) · Regeneron Pharmaceuticals, Inc. (REGN) · +75 more Most of the set sits here. 77 of the 85 companies, 39 of them with a forward estimate, priced at 5.8x in the middle of the group. What moves value here is clinical differentiation against standard of care, ownership of global rights, exclusivity runway and cash runway to the next value-inflecting readout. Biosimilars and specialty biologics 5 6% 1.6x Lantheus Holdings, Inc. (LNTH) · Alvotech (ALVO) · +3 more Five names on launched revenue. All five carry a forward estimate and the group sits at 1.6x, the bottom of the four groups on this page. These are commercial businesses, so gross-to-net erosion, payer channel economics and biosimilar entry on the revenue base are the questions that set the conversation. Diversified biopharma with marketed biologics 2 2% 5.5x AstraZeneca PLC (AZN) · Amgen Inc. (AMGN) Two large marketed platforms. AstraZeneca PLC (AZN) and Amgen Inc. (AMGN) sit at 5.5x. Large-cap biopharma facing exclusivity cliffs is the buyer group behind the top of the disclosed values in the transaction record, so this row is as much a read on demand as on price. Adjacent: research tools and diagnostics 1 1% 2.2x n=1 OPKO Health, Inc. (OPK) One adjacent name, mapped here. OPKO Health, Inc. (OPK) is the single name mapped to research tools and diagnostics, at 2.2x. Read it as the edge of the set: infrastructure, tools and services businesses are underwritten on visible earnings and capacity, which is why private capital is active at that end.

  7. 07
    SECTION 03

    03

    Divider introducing the valuation section, covering the range from early pipelines to launched revenue.

    Now we turn to valuation itself. Forward revenue is our lead lens, and as the next few pages show, the spread between the top and bottom of that range is wide.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Range Runs from Early Pipelines at the Top to Launched Revenue at the Bottom Forward revenue is the lead lens, and the spread between the tiers is wide. 03 of 06 Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Premium End Sits Alongside Early Pipelines; The Discount End Alongside Marketed Products

    Compares the 12 highest- and lowest-multiple companies among the 47 rated names against the sector median of 4.7x.

    The premium end of this range sits alongside early pipeline names, while the discount end sits alongside companies with marketed products already generating revenue. Against a sector median of 4.7x, the top and bottom groups pull in opposite directions, with the 23 names in between clustering near the median. So what: pipeline stage, not just growth, is doing real work in how the market prices these companies.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Premium End Sits Alongside Early Pipelines; The Discount End Alongside Marketed Products EV / Revenue (CY2027E) · the 12 highest and 12 lowest of 47 rated companies · sector median 4.7x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (47 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (47 of 85 companies), so this report follows it. The 23 mid-cohort names cluster near the median; the full set is in the appendix and companion tables. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM END — the 12 names at the top, largely clinical-stage pipelines with limited launched revenue · median 27.1x DISCOUNT END — the 11 names at the bottom, largely companies with products already in the market · median 1.8x Sector median 4.7x WHAT SEPARATES THE TWO ENDS The top twelve sit at 27.1x. These are mostly pipeline stories: platform validation, modality position and data still to come. The lens is forward, so a CY2027E multiple already credits forecast revenue — a premium that survives that test reads as an expectation of durability beyond the forecast window, not as a bet on next year alone. The bottom eleven sit at 1.8x. The 11 names at the bottom carry launched products and the questions that come with them: payer coverage, gross-to-net erosion and the exclusivity runway on the revenue base. Sarepta Therapeutics, Inc. (SRPT) carries -23% forward revenue growth, and a base expected to shrink is priced accordingly. Growth does not sort them cleanly. Arcus Biosciences, Inc. (RCUS) at -40% and Maze Therapeutics, Inc. (MAZE) at -30% forward revenue growth sit in the top tier, while Geron Corporation (GERN) and Ardelyx, Inc. (ARDX) grow faster than the covered middle and sit below it. Placement in the range is associated with pipeline stage and modality as much as with the near-term revenue line.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 36% Margin Line Carry 4.4x Against 1.9x Below It

    Splits rated companies by growth and by margin to show which driver correlates more strongly with valuation.

    Splitting the covered names at their median growth and margin, the margin cut shows the wider separation: names above the 36% margin line carry a 4.4x median against 1.9x below it. The growth cut is narrower — faster growers sit only modestly above slower ones. So what: profitability is associated with more of the valuation gap here than the top-line growth rate is, though the data shows association, not cause.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 36% Margin Line Carry 4.4x Against 1.9x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=18; slower n=18; higher-margin n=8; lower-margin n=7). Driver readings are NeuraCap views on the supplied data — association, not causation. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 17% · EBITDA-margin split at 36% The Faster Half Sits at 4.5x, the Slower Half at 3.9x Splitting the 36 names with a growth estimate at 17% forward revenue growth, the 18 faster-growing names sit at 4.5x and the 18 slower-growing ones at 3.9x. Against the full width of the range that step is small, so the growth rate on its own accounts for a limited part of the spread. Cash Runway to the Next Readout Is the Other Half of the Story No forward multiple tells a board whether the next registrational readout arrives inside the funded runway. In this sector that timing sits behind financing terms and partnership leverage, and it is the first screen a specialist investor runs. The Top of the Range Holds Fast Growers and Shrinking Revenue Lines Alike Arrowhead Pharmaceuticals, Inc. (ARWR) at 77% and Nurix Therapeutics, Inc. (NRIX) at 81% forward revenue growth sit in the top tier, and so do names whose revenue is expected to fall. Position at the top is associated with pipeline stage and platform validation as much as with the current revenue line. How Much of the Product Value You Keep: Owned Versus Partnered Royalty and milestone stacking dilutes the economics an acquirer inherits, and university and foundation licences frequently sit senior in the stack on early-stage assets. Two companies with the same forward revenue line can retain very different economics, and that difference is negotiated long before anyone runs a multiple.

  10. 10
    03 · SITUATION MAP

    Read Price and Growth Together and the Set Separates into Clearly Different Positions

    Places each rated company into a quadrant based on valuation versus the sector median and growth versus the covered median.

    Cutting the set on EV / Revenue against the 4.7x sector median and on growth against the 17% covered median produces four distinct positions, not one continuum. Eleven rated names without a growth estimate aren't mapped here. So what: this map is a starting point for characterising a company's situation, not a recommendation on any security.

    Everything on this page

    03 · SITUATION MAP Read Price and Growth Together and the Set Separates into Clearly Different Positions Cut on EV / Revenue vs the sector median (4.7x) (rows) and revenue growth vs the covered median (17%) (columns) · 11 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up and Growing Above-median multiple · above-median revenue growth 8 names Ascendis Pharma A/S (ASND) · BridgeBio Pharma, Inc. (BBIO) · Arrowhead Pharmaceuticals, Inc. (ARWR) · +5 more Eight of the 47 names with a forward estimate sit above the middle of the range on price and above the covered middle on revenue growth, among them Ascendis Pharma A/S (ASND), BridgeBio Pharma, Inc. (BBIO) and Nurix Therapeutics, Inc. (NRIX). The multiple already credits the ramp, so the job is holding it through the next readouts without a financing that resets the terms. Priced up, Growth Still Ahead Above-median multiple · below-median revenue growth 6 names Amgen Inc. (AMGN) · Moderna, Inc. (MRNA) · Arcus Biosciences, Inc. (RCUS) · +3 more Six names carry an above-middle multiple with below-middle revenue growth, including Amgen Inc. (AMGN), Moderna, Inc. (MRNA) and Arcus Biosciences, Inc. (RCUS). Value here sits ahead of the current revenue line, which puts the weight on the next data package and on the credibility of the pipeline behind it. Growing Faster, Priced Below the Middle Below-median multiple · above-median revenue growth 10 names Alvotech (ALVO) · Tarsus Pharmaceuticals, Inc. (TARS) · ADMA Biologics, Inc. (ADMA) · +7 more Ten names grow faster than the covered middle while pricing below it — Alvotech (ALVO), ADMA Biologics, Inc. (ADMA), Syndax Pharmaceuticals, Inc. (SNDX) and Tarsus Pharmaceuticals, Inc. (TARS) among them. Growth on its own has not moved them up the range, so the argument has to be made on owned economics, exclusivity runway and the quality of the revenue being added. Below the Middle on Both Below-median multiple · below-median revenue growth 12 names AstraZeneca PLC (AZN) · Regeneron Pharmaceuticals, Inc. (REGN) · Lantheus Holdings, Inc. (LNTH) · +9 more Twelve names sit below the middle on both measures, including AstraZeneca PLC (AZN), Regeneron Pharmaceuticals, Inc. (REGN) and PTC Therapeutics, Inc. (PTCT). Scale and marketed revenue are being underwritten with exclusivity cliffs and payer pressure in view, which is also what makes several of them active buyers.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Four Names Clear Both Bars — Growth and Margin Together

    Plots the 15 companies with both growth and margin estimates into quadrants cut at the covered medians.

    Among the 15 names with both a growth and a margin estimate, only four clear both the 14% growth and 36% margin bars at once. Each quadrant carries its own median EV / Revenue, so being in the balanced group also comes with a different valuation outcome. So what: clearing both bars together is rare enough in this data that it stands out as a distinct position.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Four Names Clear Both Bars — Growth and Margin Together Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 15 companies with both estimates · cuts at the covered medians (14% growth, 36% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=4; margin-only n=4; growth-only n=4; neither n=3). Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 -20% 0% 20% 40% 60% 20% 40% 60% MARGIN ONLY median 4.1x BALANCED median 4.7x NEITHER median 1.9x GROWTH ONLY median 2.7x SRPT AMGN AZN REGN PTCT LNTH ACAD TLX EOLS AUPH ADMA ALVO ARDX ASND BBIO x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS This page maps the 15 names that carry both a forward growth and a forward margin estimate, split at 14% growth and 36% margin. Four clear both bars — Aurinia Pharmaceuticals Inc. (AUPH), ADMA Biologics, Inc. (ADMA), Alvotech (ALVO) and Ascendis Pharma A/S (ASND) — and they sit at 4.7x, against 4.1x for the four with margin alone, 2.7x for the four with growth alone and 1.9x for the three with neither. The growth-only median rests on 4 names and is lifted by BBIO at 7.5x. The neither median rests on 3 names and is lifted by LNTH at 4.0x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 11 of 15 names clear it.

  12. 12
    03 · THE AGENDA

    The Decisions an Owner Weighs Against What This Market Rewards

    Frames the questions an owner or acquirer should resolve given what this market rewards.

    Given what we've just shown on growth, margin and pipeline stage, this page frames the practical questions an owner should be resolving now. These are observations drawn from the cohort data, not recommendations to buy or sell. So what: the agenda gives management a concrete checklist tied directly to what the market is actually pricing.

    Everything on this page

    03 · THE AGENDA The Decisions an Owner Weighs Against What This Market Rewards NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Defend and Extend Premium names protect the franchise the multiple already prices. What changes the answer: Two quarters of decelerating growth. Prove the Re-Rating Discounted growers close the gap with evidence, not narrative. What changes the answer: Growth sustained above the covered median. Fix the Economics Below-median margins are the controllable lever. What changes the answer: Margin trajectory crossing the cohort median. Test the Market Where public credit is absent, the precedent transactions is the second opinion. What changes the answer: A comparable transaction printing above the public median.

  13. 13
    SECTION 04

    04

    Divider introducing the precedent-transactions section covering nine recorded deals.

    Next we turn to what buyers have actually agreed to pay — four completed and five announced transactions recorded between June and September 2026.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS What Buyers Agreed to Pay Across Nine Recorded Transactions Four completed and five announced, recorded between June and September 2026. 04 of 06 Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    What Buyers Agreed to Pay for Whole Companies, June to September 2026

    Presents three of the recorded transactions as detailed case studies on the price buyers paid for whole companies.

    Of the transactions with disclosed terms, we walk through three as case studies, including argenx SE's completed acquisition of Forte Biosciences, Inc. at $11.3B and AbbVie Inc.'s completed acquisition of Apogee Therapeutics, Inc. at $10.8B. Deal multiples here are calculated on LTM financials at announcement, a different basis from the forward public multiples elsewhere in this report, so we don't draw a spread between them. So what: the largest disclosed values went to clinical-stage targets, a pattern consistent with large biopharma adding externally validated science ahead of exclusivity cliffs.

    Everything on this page

    04 · DEAL CASE STUDIES What Buyers Agreed to Pay for Whole Companies, June to September 2026 3 of 51 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 94 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; no evidence record); figures are shown as recorded in the filing. 80 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Mar-2023 $2.9B Sanofi S.A. acquires Provention Bio EV / LTM revenue 4.9x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Acquisitions in this set follow a consistent logic: a buyer with commercial infrastructure takes on an asset it can carry through registration and launch, and engagement typically begins with a collaboration or option-to-license structure before the acquisition follows data. HOW THE TARGET WAS VALUED Underwriting runs asset by asset on risk-adjusted NPV, with probability of technical and regulatory success and exclusivity runway doing most of the work. Against the peer set, where a company lands in the range moves with pipeline stage and with how much of the global rights it owns. Nov-2025 $2.3B Servier Pharmaceuticals LLC acquires Day One Biopharmaceuticals, Inc. EV / LTM revenue 14.6x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Buyers in biotechnology price control of the asset, the regulatory path and the supply chain, which is why whole-company acquisitions sit alongside territorial licensing for the same science. Where buyer and seller read a readout differently, contingent value rights bridge the gap. HOW THE TARGET WAS VALUED Headline value and cash at signing diverge here: upfront consideration is routinely blended with development, regulatory and commercial milestones plus tiered royalties. The benchmark that matters to an owner is the retained economics after the royalty and licence stack, not the announced total. Jun-2026 $1.3B Zymeworks Inc. Zymeworks Inc. completed its acquisition of Theravance Biopharma, Inc. at $1.3B in June 2026. EV / LTM revenue 11.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED A clinical-stage buyer taking on a company with marketed and royalty economics is the shape used when a pipeline needs funding that is not purely dilutive. The transaction suggests the buyer valued an established commercial and partnering position alongside its own development programmes. HOW THE TARGET WAS VALUED The recorded value is $1.3B at 11.4x revenue. That sits well above the middle of the peer set on this page, which places it among the transactions underwritten on what the asset base can become rather than on current billings.

  15. 15
    SECTION 05

    05

    Divider introducing the strategic-implications section on what moves a name up the valuation range.

    With the pricing picture and the deal record in view, we close on what actually moves a company up this range — the operating decisions that show up in how it gets underwritten.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS What Moves a Name up the Range from Here Operating decisions that show up in how a company is underwritten. 05 of 06 Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    What to Strengthen Before the Next Readout: Mix, Pricing and Capital Allocation

    Sets out what owners, management teams and boards should strengthen around mix, pricing and capital allocation.

    For owners, the peer set should follow the business rather than the sector label, since clinical-stage pipelines and launched biologics revenue are read on different evidence entirely. For management teams, growth rate alone moves the multiple only a short distance, so pipeline differentiation, exclusivity runway and margin trajectory carry more of the weight. For boards, the transaction record itself is a live reference point for any build-versus-buy decision. So what: this page turns the pricing pattern into a set of concrete questions for the next twelve months.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS What to Strengthen Before the Next Readout: Mix, Pricing and Capital Allocation NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Know Which Half of This Market Your Revenue Belongs To Clinical-stage pipelines and launched biologics revenue are read on different evidence, and the peer set a board uses should follow the business rather than the sector label. Choosing the wrong peers understates or overstates the company's position before a single number is argued. FOR MANAGEMENT TEAMS Growth Rate Alone Moves the Multiple a Short Distance The faster-growing half of the names with a growth estimate sits only a step above the slower half, while the full range runs far wider. The differences that travel are pipeline stage, differentiation against standard of care, exclusivity runway and how much of the product economics the company retains. FOR BOARDS AND CAPITAL ALLOCATORS Build-Versus-Buy Is Being Answered in the Transaction Record Large-cap biopharma facing exclusivity cliffs has been paying at the top of the disclosed values for clinical-stage assets, while small absolute values changed hands at the other end. That spread is the practical reference for any decision to in-license, partner or acquire rather than develop internally.

  17. 17
    SECTION 06

    06

    Divider introducing the appendix covering the full comparables universe, methodology and sources.

    The final section lays out the full comparables set, the precedent-transaction list, and the methodology behind every figure in this report.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    Lists public comparables on EV / Revenue by valuation tier for part of the rated universe.

    This page lists comparables from the 47 rated companies, shaded by whether each sits above or below the 4.7x sector median. 38 of the 85 companies have no eligible EV / Revenue multiple and are not rated here. So what: this is the underlying detail a reader can check company by company behind every multiple quoted earlier in the deck.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.7x); amber marks below · 47 rated companies; 38 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 31 of 47 rated names shown here; the remaining 16 rows are in the companion workbook beside this deck. Names without an eligible multiple are listed in the companion workbook. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥11.6x · median 27.1x · 12 companies Vaxcyte, Inc. PCVX Diversified clinical-stage biotech $6.8B 77.9x n/a n/a n/a Maze Therapeutics, Inc. MAZE Diversified clinical-stage biotech $1.0B 75.1x -31% n/a n/a Arcus Biosciences, Inc. RCUS Diversified clinical-stage biotech $2.4B 52.0x -40% n/a n/a Moderna, Inc. MRNA Diversified clinical-stage biotech $74.4B 31.1x 14% n/a n/a MoonLake Immunotherapeutics MLTX Diversified clinical-stage biotech $594M 31.0x n/a n/a n/a Greenwich LifeSciences, Inc. GLSI Diversified clinical-stage biotech $262M 30.0x n/a n/a n/a CRISPR Therapeutics AG CRSP Diversified clinical-stage biotech $3.6B 24.1x n/a n/a n/a IDEAYA Biosciences, Inc. IDYA Diversified clinical-stage biotech $2.7B 23.5x n/a n/a n/a Arrowhead Pharmaceuticals, Inc. ARWR Diversified clinical-stage biotech $8.4B 18.8x 77% n/a n/a Denali Therapeutics Inc. DNLI Diversified clinical-stage biotech $2.4B 18.3x n/a n/a n/a Nurix Therapeutics, Inc. NRIX Diversified clinical-stage biotech $2.0B 15.4x 81% n/a n/a Bright Minds Biosciences Inc. DRUG Diversified clinical-stage biotech $273M 12.1x n/a n/a n/a CORE — 3.3x–11.6x · median 4.6x · 24 companies Genelux Corporation GNLX Diversified clinical-stage biotech $87M 11.1x n/a n/a n/a Editas Medicine, Inc. EDIT Diversified clinical-stage biotech $194M 10.0x -25% n/a n/a Cibus, Inc. CBUS Diversified clinical-stage biotech $114M 9.2x n/a n/a n/a

  19. 19
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    Continues the public comparables list on EV / Revenue by valuation tier.

    This page continues the comparables list from the previous page, completing the rated set of 47 companies shown against the 4.7x sector median. Teal shading marks names above the median and amber marks those below it. So what: together with the prior page, this gives a reader the full rated universe behind the deck's valuation claims.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.7x); amber marks below · 47 rated companies; 38 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 31 of 47 rated names shown here; the remaining 16 rows are in the companion workbook beside this deck. Names without an eligible multiple are listed in the companion workbook. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 3.3x–11.6x · median 4.6x · 24 companies CytomX Therapeutics, Inc. CTMX Diversified clinical-stage biotech $242M 8.0x 20% n/a n/a BridgeBio Pharma, Inc. BBIO Diversified clinical-stage biotech $12.7B 7.5x 65% 12% 77 Ginkgo Bioworks Holdings, Inc. DNA Diversified clinical-stage biotech $682M 7.1x 13% n/a n/a Amgen Inc. AMGN Diversified biopharma with marketed biologics $271B 6.7x 4% 45% 48 Ascendis Pharma A/S ASND Diversified clinical-stage biotech $14.6B 6.4x 46% 36% 82 OKYO Pharma Limited OKYO Diversified clinical-stage biotech $47M 5.8x n/a n/a n/a Nuvation Bio Inc. NUVB Diversified clinical-stage biotech $1.5B 5.3x 42% n/a n/a Aurinia Pharmaceuticals Inc. AUPH Diversified clinical-stage biotech $1.9B 4.8x 18% 65% 82 Zai Lab Limited ZLAB Diversified clinical-stage biotech $2.4B 4.7x 21% n/a n/a Alvotech ALVO Biosimilars and specialty biologics $3.3B 4.6x 22% 38% 60 MediWound Ltd. MDWD Diversified clinical-stage biotech $142M 4.5x 34% n/a n/a Prelude Therapeutics Incorporated PRLD Diversified clinical-stage biotech $248M 4.4x 24% n/a n/a AstraZeneca PLC AZN Diversified biopharma with marketed biologics $284B 4.2x 7% 37% 43 Lantheus Holdings, Inc. LNTH Biosimilars and specialty biologics $6.6B 4.0x 12% 36% 48 Wave Life Sciences Ltd. WVE Diversified clinical-stage biotech $177M 3.9x -12% n/a n/a Regeneron Pharmaceuticals, Inc. REGN Diversified clinical-stage biotech $72.8B 3.9x 9% 38% 47

  20. 20
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    Lists precedent transactions with disclosed terms, newest first, out of the full recorded set.

    This page lists transactions with disclosed terms out of the full recorded set, with multiples calculated on LTM financials at announcement where disclosed. A portion of the recorded transactions carry data-quality flags or lack a disclosed value or multiple and are held in the companion workbook instead. So what: this is the transaction-level evidence behind the deal patterns discussed earlier in the report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 51 transactions with disclosed terms in this tier (131 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 94 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; no evidence record); figures are shown as recorded in the filing. 80 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 51 transactions shown; the rest are in the companion workbook. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Sep-2026 Xenetic Biosciences, Inc. → Santersus AG $141M n/a n/a Xenetic Biosciences, Inc. announced the acquisition of Santersus AG at $141M in September 2026. Small-cap acquirers use transactions of this size to add a platform or asset that changes the story they can tell about their pipeline. Aug-2026 Jazz Pharmaceuticals, Inc. → Actio Biosciences, Inc. $820M n/a n/a Jazz Pharmaceuticals, Inc. completed its acquisition of Actio Biosciences, Inc. at $820M in August 2026. A specialty acquirer with an established neuroscience and rare disease franchise taking on a clinical-stage target fits the consolidation pattern in this record. Jul-2026 Sonic Holdco, Inc. → Synlogic, Inc. $3M n/a n/a Sonic Holdco, Inc. announced the acquisition of Synlogic, Inc. at $3M in July 2026. Values at this level are consistent with a corporate shell or residual asset changing hands rather than with a funded clinical programme. Jul-2026 argenx SE → Forte Biosciences, Inc. $11.3B n/a n/a argenx SE completed its acquisition of Forte Biosciences, Inc. at $11.3B in July 2026. A commercial-stage immunology buyer taking on a clinical-stage immunology asset is the shape large-cap biopharma has been using to add externally validated science. Jul-2026 Celadon Partners, LLC → Senti Holdings, Inc. $55M 55.3x n/a Celadon Partners, LLC announced the acquisition of Senti Holdings, Inc. at $55M in July 2026, recorded at 55.3x revenue. A financial buyer taking a cell therapy platform at a small absolute value points to an asset priced on what the technology may become rather than… Jul-2026 Azurity Pharmaceuticals, Inc. → Matinas BioPharma Holdings, Inc. $21500B n/a n/a Azurity Pharmaceuticals, Inc. announced the acquisition of Matinas BioPharma Holdings, Inc. in July 2026. A specialty pharmaceutical acquirer adding a drug delivery platform is a route to extending formulations across a marketed portfolio it already sells through. Jul-2026 Omid Farokhzad, M.D. → Seer, Inc. $114M 8.0x n/a Omid Farokhzad, M.D. is recorded as the acquirer of Seer, Inc. at $114M in July 2026, announced at 8.0x revenue. Proteomics tools sit adjacent to the therapeutic set, and they are underwritten on instrument and consumable economics rather than on pipeline value. Jun-2026 Zymeworks Inc. → Theravance Biopharma, Inc. $1.3B 11.4x n/a Zymeworks Inc. completed its acquisition of Theravance Biopharma, Inc. at $1.3B in June 2026, recorded at 11.4x revenue. A clinical-stage buyer adding a company with commercial and royalty economics is a familiar way to fund a pipeline. Jun-2026 AbbVie Inc. → Apogee Therapeutics, Inc. $10.8B n/a n/a AbbVie Inc. completed its acquisition of Apogee Therapeutics, Inc. at $10.8B in June 2026. The buyer already carries the commercial infrastructure an inflammation and immunology asset needs, which is the classic argument for buying rather than building.

  21. 21
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    Continues the list of precedent transactions with disclosed terms, newest first.

    This page continues the precedent-transaction list, completing the disclosed-terms subset shown here. Multiples continue to be calculated on LTM financials at announcement, consistent with the prior page. So what: between the two pages, a reader has the full disclosed-terms record referenced throughout this report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 51 transactions with disclosed terms in this tier (131 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 94 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate filings collapsed; no evidence record); figures are shown as recorded in the filing. 80 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 51 transactions shown; the rest are in the companion workbook. Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2026 n/a → Biocryst Pharmaceuticals, Inc. n/a 2.2x n/a Value shown as recorded in the filing; status defaulted announced. Apr-2026 Cyclerion Therapeutics, Inc. → Korsana Biosciences, Inc. $380M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2026 Kuva Labs Inc. → Lisata Therapeutics, Inc. $18M 90.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Jan-2026 Eli Lilly and Company → Ventyx Biosciences, Inc. $976M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Nov-2025 Servier Pharmaceuticals LLC → Day One Biopharmaceuticals, Inc. $2.3B 14.6x n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2025 Novo Nordisk A/S → Akero Therapeutics, Inc. $4.5B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2025 Zydus Pharmaceuticals (USA) Inc. → Agenus Inc. $154M 1.4x n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2025 SERB S.a.r.l. → Y-mAbs Therapeutics, Inc. n/a 3.4x n/a Apr-2025 Merck KGaA → SpringWorks Therapeutics, Inc. n/a 2.6x n/a

  22. 22
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Explains the report's sources, valuation basis, and data-quality exclusions.

    This page sets out the valuation basis, EV / Revenue on CY2027E consensus, the sources behind the analysis, and the data-quality decisions that shaped what is shown and what was excluded. It also explains why the report follows the industry's standard practice of pricing this sector on forward revenue rather than forward EBITDA, given the coverage available. So what: it lets a reader trace any figure in this report back to how it was built.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Biotechnology Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (47 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (47 of 85 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Biotechnology and it clears the coverage gate with 47 of 85 companies (55%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (15 of 85 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 397 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 2172 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (2171) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  23. 23

    Across 85 Biotechnology Names, Where a Company Sits in the Range Is Worth Defending.

    Closing statement that a company's position in the biotechnology valuation range is worth defending.

    Across the 85 biotechnology names in this universe, where a company sits in the range is worth defending. The companion tables carry the full universe and source index for any figure a client wants to trace further.

    Everything on this page

    Across 85 Biotechnology Names, Where a Company Sits in the Range Is Worth Defending. NeuraCap AI — Biotechnology Coverage September 2026 · Prepared by NeuraCap AI · Confidential Biotechnology Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23

Sources and methodology

This report covers Biotechnology (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Biotechnology) with market data and consensus estimates as of September 28, 2026. The company universe is the 85 listed companies whose core business is Biotechnology according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc. Common Stock (ACOG), ADMA Biologics, Inc. (ADMA), Aldeyra Therapeutics, Inc. (ALDX), Alumis Inc. Common Stock (ALMS), Alvotech (ALVO), Amgen Inc. (AMGN), Annexon, Inc. (ANNX), Alto Neuroscience, Inc. (ANRO), Ardelyx, Inc. (ARDX), Arrowhead Pharmaceuticals, Inc. (ARWR), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), ArriVent BioPharma, Inc. Common Stock (AVBP), AstraZeneca PLC (AZN), BridgeBio Pharma, Inc. (BBIO), BridgeBio Oncology Therapeutics Inc. (BBOT), BioAge Labs, Inc. (BIOA), Belite Bio, Inc (BLTE), Cibus, Inc. (CBUS), Celcuity Inc. (CELC), Climb Bio, Inc. (CLYM), COMPASS Pathways plc (CMPS), Cogent Biosciences, Inc. (COGT), Cardiff Oncology, Inc. (CRDF), CRISPR Therapeutics AG (CRSP), CytomX Therapeutics, Inc. (CTMX), Ginkgo Bioworks Holdings, Inc. (DNA), Denali Therapeutics Inc. (DNLI), Bright Minds Biosciences Inc. (DRUG), Emergent BioSolutions Inc. (EBS), Editas Medicine, Inc. (EDIT), Elicio Therapeutics, Inc. (ELTX), Evolus, Inc. (EOLS), EyePoint Pharmaceuticals, Inc. (EYPT), Fortress Biotech, Inc. (FBIO), Fulcrum Therapeutics, Inc. (FULC), Gain Therapeutics, Inc. (GANX), Geron Corporation (GERN), Greenwich LifeSciences, Inc. (GLSI), Genelux Corporation (GNLX), HUTCHMED (China) Limited (HCM), IDEAYA Biosciences, Inc. (IDYA), Inovio Pharmaceuticals, Inc. (INO), Disc Medicine, Inc. (IRON), Kalaris Therapeutics Inc (KLRS), Keros Therapeutics, Inc. (KROS), LB Pharmaceuticals Inc Common Stock (LBRX), Lantheus H

Scope and company universe

This report covers Biotechnology (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Biotechnology) with market data and consensus estimates as of September 28, 2026. The company universe is the 85 listed companies whose core business is Biotechnology according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc. Common Stock (ACOG), ADMA Biologics, Inc. (ADMA), Aldeyra Therapeutics, Inc. (ALDX), Alumis Inc. Common Stock (ALMS), Alvotech (ALVO), Amgen Inc. (AMGN), Annexon, Inc. (ANNX), Alto Neuroscience, Inc. (ANRO), Ardelyx, Inc. (ARDX), Arrowhead Pharmaceuticals, Inc. (ARWR), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), ArriVent BioPharma, Inc. Common Stock (AVBP), AstraZeneca PLC (AZN), BridgeBio Pharma, Inc. (BBIO), BridgeBio Oncology Therapeutics Inc. (BBOT), BioAge Labs, Inc. (BIOA), Belite Bio, Inc (BLTE), Cibus, Inc. (CBUS), Celcuity Inc. (CELC), Climb Bio, Inc. (CLYM), COMPASS Pathways plc (CMPS), Cogent Biosciences, Inc. (COGT), Cardiff Oncology, Inc. (CRDF), CRISPR Therapeutics AG (CRSP), CytomX Therapeutics, Inc. (CTMX), Ginkgo Bioworks Holdings, Inc. (DNA), Denali Therapeutics Inc. (DNLI), Bright Minds Biosciences Inc. (DRUG), Emergent BioSolutions Inc. (EBS), Editas Medicine, Inc. (EDIT), Elicio Therapeutics, Inc. (ELTX), Evolus, Inc. (EOLS), EyePoint Pharmaceuticals, Inc. (EYPT), Fortress Biotech, Inc. (FBIO), Fulcrum Therapeutics, Inc. (FULC), Gain Therapeutics, Inc. (GANX), Geron Corporation (GERN), Greenwich LifeSciences, Inc. (GLSI), Genelux Corporation (GNLX), HUTCHMED (China) Limited (HCM), IDEAYA Biosciences, Inc. (IDYA), Inovio Pharmaceuticals, Inc. (INO), Disc Medicine, Inc. (IRON), Kalaris Therapeutics Inc (KLRS), Keros Therapeutics, Inc. (KROS), LB Pharmaceuticals Inc Common Stock (LBRX), Lantheus Holdings, Inc. (LNTH), Maze Therapeutics, Inc. (MAZE), MediWound Ltd. (MDWD), Jyong Biotech Ltd. Ordinary Shares (MENS), MoonLake Immunotherapeutics (MLTX), MediciNova, Inc. (MNOV), Moderna, Inc. (MRNA), Nurix Therapeutics, Inc. (NRIX), Nuvation Bio Inc. (NUVB), OKYO Pharma Limited (OKYO), Oncolytics Biotech Inc. (ONCY), OPKO Health, Inc. (OPK), ORIC Pharmaceuticals, Inc. (ORIC), Palisade Bio, Inc. (PALI), Vaxcyte, Inc. (PCVX), Pliant Therapeutics, Inc. (PLRX), PMV Pharmaceuticals, Inc. (PMVP), Prelude Therapeutics Incorporated (PRLD), PTC Therapeutics, Inc. (PTCT), Palvella Therapeutics, Inc. (PVLA), Arcus Biosciences, Inc. (RCUS), Regeneron Pharmaceuticals, Inc. (REGN), Atrium Therapeutics, Inc. (RNA), Cartesian Therapeutics, Inc. (RNAC), Roivant Sciences Ltd. (ROIV), Revolution Medicines, Inc. (RVMD), Syndax Pharmaceuticals, Inc. (SNDX), Sarepta Therapeutics, Inc. (SRPT), Tarsus Pharmaceuticals, Inc. (TARS), Tectonic Therapeutic, Inc. (TECX), Telix Pharmaceuticals Limited (TLX), Tonix Pharmaceuticals Holding Corp. (TNXP), Tyra Biosciences, Inc. (TYRA), Vera Therapeutics, Inc. (VERA), Wave Life Sciences Ltd. (WVE), Xeris Biopharma Holdings, Inc. (XERS), Zai Lab Limited (ZLAB). The market map groups them by business vertical — Diversified clinical-stage biotech: 77 companies (MRNA, REGN, RVMD, ROIV, ASND, BBIO, ARWR, PCVX, BLTE, COGT, TLX, PTCT, CELC, CRSP, TARS, IDYA, ACAD, RCUS, ZLAB, ADMA, DNLI, SRPT, NRIX, AUPH, XERS, VERA, IRON, PVLA, SNDX, NUVB, ORIC, MAZE, AVBP, TYRA, CMPS, ARDX, LBRX, ANRO, DNA, GERN, ANNX, MLTX, CLYM, ALMS, DRUG, GLSI, PRLD, CTMX, TECX, EDIT, WVE, MDWD, ACOG, PALI, CBUS, RNAC, GNLX, MNOV, EYPT, ONCY, GANX, BBOT, INO, OKYO, CRDF, ELTX, ALDX, MENS, BIOA, FBIO, FULC, KLRS, KROS, PLRX, PMVP, RNA, TNXP); Biosimilars and specialty biologics: 5 companies (LNTH, ALVO, HCM, EBS, EOLS); Diversified biopharma with marketed biologics: 2 companies (AZN, AMGN); Adjacent: research tools and diagnostics: 1 company (OPK). 47 of the 85 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

397 records failed a validation gate and never feed a statistic in this report (352 excluded from aggregate; 45 quarantined). Each exclusion, with its reason: ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACOG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ALMS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ALMS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ALMS — Implied EBITDA margin -1285.9% outside the plausible band [-100%, 80%] (effect: quarantined) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Revenue for CY2026E is 0.27x the CY2025A value and 4.2x smaller than CY2027E; the value is on a different basis from the periods either side of it and cannot be compared with them (effect: quarantined) · ALVO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALVO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANRO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ANRO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (47 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (47 of 85 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Biotechnology and it clears the coverage gate with 47 of 85 companies (55%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (15 of 85 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 15 of 85 companies; EV / rEVenue: 65 of 85 companies; P/E: 17 of 85 companies. 7 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 61 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥11.6x, Core 3.3x–11.6x, Discount <3.3x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 4.7x = median(ev_revenue CY2027E) (47 rated companies) · 27.1x = median(ev_revenue CY2027E) within Premium tier (n=12) · 4.6x = median(ev_revenue CY2027E) within Core tier (n=24) · 1.8x = median(ev_revenue CY2027E) within Discount tier (n=11) · 4.5x = median(ev_revenue CY2027E) | growth ≥ 17% (n=18) · 3.9x = median(ev_revenue CY2027E) | growth < 17% (n=18) · 4.4x = median(ev_revenue CY2027E) | EBITDA margin ≥ 36% (n=8) · 1.9x = median(ev_revenue CY2027E) | EBITDA margin < 36% (n=7) · 47% = median Rule of 40 score (revenue growth + EBITDA margin) (n=15) · 4.7x = median(ev_revenue CY2027E) within balanced quadrant (n=4) · 4.1x = median(ev_revenue CY2027E) within marginOnly quadrant (n=4) · 2.7x = median(ev_revenue CY2027E) within growthOnly quadrant (n=4) · 1.9x = median(ev_revenue CY2027E) within neither quadrant (n=3) · 7.5x = ev_revenue CY2027E for BBIO (quadrant outlier) · 4.0x = ev_revenue CY2027E for LNTH (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Biotechnology recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 131 transactions were recorded for this industry; 51 are shown. 80 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 64 × deal value unit unresolved; 29 × no evidence record; 1 × duplicate filings collapsed. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 2176 source documents stand behind this report; by publisher domain: sec.gov (2171), home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Biotechnology?

Company valuation reports run the same method against a single business — public or private.